Dr. Alexander Rivkin Co-Authors Landmark Phase 2B Study on OnabotulinumtoxinA for Masseter Muscle Prominence Published in Aesthetic Surgery Journal
Internationally renowned aesthetic expert Dr. Alexander Rivkin contributes to groundbreaking research demonstrating the safety and efficacy of Botox® treatment for masseter muscle prominence reduction. The comprehensive study, published in the prestigious Aesthetic Surgery Journal, represents a significant advancement in non-surgical facial contouring treatments.
LOS ANGELES, June 2, 2025 /PRNewswire/ -- Dr. Alexander Rivkin, globally recognized pioneer in non-surgical rhinoplasty and facial aesthetic procedures, has co-authored a pivotal Phase 2B clinical study demonstrating the safety and efficacy of onabotulinumtoxinA (Botox®) for treating masseter muscle prominence. The comprehensive research, titled "A Controlled Phase 2b Trial to Assess the Efficacy and Safety of a Single Intervention of OnabotulinumtoxinA for Treating Masseter Muscle Prominence," has been published in the prestigious Aesthetic Surgery Journal and is accessible at https://academic.oup.com/asj/advance-article/doi/10.1093/asj/sjaf042/8088127?login=false.
Dr. Rivkin collaborated with leading international researchers including Dr. Steven Liew, Dr. Derek Jones, Dr. Steven Dayan, Dr. Sabrina Fabi, and Dr. Brian Biesman on this landmark multicenter, randomized, double-blind, placebo-controlled trial. The study evaluated the effectiveness of onabotulinumtoxinA in reducing masseter muscle prominence—a condition that can create a wide, square jawline appearance and affect facial aesthetics.
The research findings demonstrated that onabotulinumtoxinA administered in single or multiple treatments over one year was associated with significant reductions in masseter muscle volume and prominence severity, while maintaining an acceptable safety profile. The study represents a major advancement in understanding how botulinum toxin can be safely and effectively used for lower facial contouring.
"This research represents an important milestone in expanding our treatment options for patients seeking non-surgical facial enhancement," said Dr. Rivkin. "The results provide valuable clinical evidence supporting the use of onabotulinumtoxinA for masseter muscle prominence, allowing us to offer patients a safe, effective solution for achieving more refined facial contours without surgery."
The comprehensive study involved multiple international clinical sites and represents years of meticulous research and data collection. For patients with masseter muscle prominence—often characterized by a square or wide lower face appearance—this treatment offers a minimally invasive alternative to surgical interventions. The research findings support the growing trend toward non-surgical facial contouring procedures that can achieve significant aesthetic improvements with minimal downtime.
Dr. Rivkin's participation in this landmark study underscores his commitment to advancing the field of aesthetic medicine through rigorous clinical research. As a leader in non-surgical facial treatments and pioneer of the non-surgical rhinoplasty technique, Dr. Rivkin continues to contribute to the scientific literature that guides best practices in aesthetic medicine.
More About Dr. Alexander RivkinDr. Alexander Rivkin is a facial aesthetic specialist and Assistant Clinical Professor at the David Geffen School of Medicine at UCLA. He received his undergraduate degree from Columbia University and his medical degree from Yale University School of Medicine, his residency in Otolaryngology/Head and Neck Surgery was at the University of California, San Diego. Dr. Rivkin is globally recognized as a pioneer in non-surgical rhinoplasty and has authored numerous peer-reviewed publications on aesthetic procedures.
Dr. Rivkin's practice, RIVKIN Aesthetics, is located in Beverly Hills and Los Angeles, offering cutting-edge non-surgical facial treatments and aesthetic procedures. The practice is renowned for natural-looking results and innovative treatment approaches that prioritize patient safety and satisfaction.
For more information about Dr. Alexander Rivkin or to schedule a consultation, please visit www.westsideaesthetics.com.
Media ContactDr. Alexander RivkinRIVKIN Aesthetics(310) 443-5273www.westsideaesthetics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/dr-alexander-rivkin-co-authors-landmark-phase-2b-study-on-onabotulinumtoxina-for-masseter-muscle-prominence-published-in-aesthetic-surgery-journal-302470522.html
SOURCE RIVKIN Aesthetics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Rhône Valley's Côtes du Rhône and Côtes du Rhône Villages AOCs Increase Focus on Wine Tourism
The vibrant spirit and unique experiences put the region in a prime position to draw in visitors, both domestic and international, even further NEW YORK, June 4, 2025 /PRNewswire/ -- Inter Rhône, the organization that represents the Rhône Valley Vineyards AOCs, is happy to share that the Côtes du Rhône and Côtes du Rhône Villages AOCs, two significant appellations of the Rhône Valley, are concentrating on new and exciting wine tourism events and activities for consumers to explore this historic, dynamic part of the region. According to the French Ministry of Tourism, France is the world's leading tourist destination. The past few years have seen continued growth, with 2023 and 2024 seeing a record number of over 100 million visitors. The global wine tourism market is also expected to see continued growth over the next 10 years. The Côtes du Rhône, then, is poised to welcome visitors to this one-of-a-kind region: Imagine sipping wine under the sun, surrounded by medieval villages and rolling vineyards - the Côtes du Rhône is the ultimate getaway for adventure seekers, families, foodies, and culture lovers alike. Cultural and Historical WondersThe Côtes du Rhône is rich in history, with four UNESCO World Heritage sites, from the majestic Palais des Papes in Avignon, a 14th-century Gothic palace that once served as the residence of popes, to the Pont du Gard, an ancient Roman aqueduct that stands as a marvel of engineering. Stepping back even further, the Grotte Chauvet 2 cave in Ardèche, an accurate replica of the original Chauvet Caves, showcases prehistoric art that is over 30,000 years old. The stunning wine-producing villages of Séguret, Aiguèze, and La Roque-sur-Cèze truly capture the heart of the Côtes du Rhône with their beautiful scenery. Sip, Savor, RepeatFor epicures, the Côtes du Rhône is home to a wide range of wines, from expressive reds and crisp whites to delicate rosés, paired with local delights like black truffles, creamy goat cheese, and Nyons olives for the ultimate tasting experience. Gastronomic experiences abound in the Côtes du Rhône, including chic bistros and picnics in the vineyards. Festivals, Music, and Good VibesThe Côtes du Rhône is known for its exciting fêtes, from lively music festivals to gourmet food events. Whether tasting through a wine festival or experiencing a traditional celebration, there is always a reason to raise a glass! Nature, but Make It FunFor visitors looking for outdoor adventures, the Côtes du Rhône is full of activities, from cycling through the vineyards on the scenic EuroVelo 17 (aka 'Via Rhôna'), hiking through breathtaking landscapes, to taking a guided wine walk. Sustainability is key here, and the region is dedicated to preserving its natural beauty. Wine Tourism: A New EraWineries here are leaning into consumer interests - moving away from stuffy tastings and shaking things up with even more hands-on experiences, such as blending workshops, themed tastings, sensory tastings, massages in the vineyards, and overnight vineyard stays. The Côtes du Rhône region is appealing to those who are wine newbies, as well as to seasoned connoisseurs, with a wide range of unique experiences and something for everyone. Tourists interested in planning an unforgettable trip to the Côtes du Rhône can for insider tips and must-visit spots. About Côtes du Rhône and Côtes du Rhône Villages AOCsCôtes du Rhône and Côtes du Rhône Villages AOCs are two significant appellations within the Rhône Valley wine region of France, renowned for their diverse and high-quality wines. Côtes du Rhône AOC (Appellation d'Origine Contrôlée) is one of the largest and most renowned appellations in France, covering vast vineyard areas along the Rhône River. It encompasses both the Northern and Southern Rhône regions, allowing for a wide range of grape varieties and wine styles. Produced in 172 communes on rich and varied terroirs, regional Côtes du Rhône is notable for its diversity, its character and a blend that guarantees a quality wine. Côtes du Rhône Villages AOC represents a step up in quality and specificity within the Côtes du Rhône appellation. This designation is reserved for wines that meet stricter production standards and come from specific communes or villages within the Rhône Valley. The regulations limit yields and dictate stricter guidelines for grape growing and winemaking practices, ensuring higher quality standards. Within the Côtes du Rhône Villages AOC, there are also specific villages entitled to append their name to the label, denoting even higher quality standards. There are 21 such villages, each recognized for their unique terroir and historical winemaking traditions. For more information, please visit and for photos, please visit Press Contacts:Erin HealyColangelo & Partnersehealy@ Béatrice MialonInter Rhônebmialon@inter-rhô View original content to download multimedia: SOURCE Inter Rhône Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Propedix Inc. Announces Appointment of William Haegele to Board of Directors
BOSTON, June 4, 2025 /PRNewswire/ -- Propedix, a leading organization in Anti-infective topical Dermatology treatments, is pleased to announce a significant addition to its Board of Directors. Bill Haegele has been appointed to the Board of Directors as its first Independent Director and will play a pivotal role in driving the company's strategic initiatives and fostering continued growth. Propedix's first product, Dryello™ is a soon to be launched over-the-counter treatment for Athlete's Foot (tinea pedis), intended to both treat and prevent the fungal infection and its symptoms. With a proven track record of success in life sciences, public accounting, board governance, and general management, Mr. Haegele brings a wealth of experience and expertise to Propedix. A retired KPMG Partner, he offers deep knowledge in corporate governance and risk management. Bill has held leadership and board roles at several life sciences companies and is widely recognized for his innovative thinking, strategic leadership, and comprehensive understanding of the industry landscape. "We are thrilled to welcome Bill to the Board of Directors," said Niv Caviar, CEO of Propedix. "His visionary approach, strategic mindset, and passion for life science innovation align perfectly with our company's values and objectives. We are confident that his leadership will help propel us to new heights and reinforce our position as an industry leader." In this role, Bill will provide governance oversight over the company's financial, accounting, and corporate functions. His strategic vision and ability to help grow the company will be instrumental in guiding Propedix towards continued success and expansion as the Company develops and launches innovative dermatological topical anti-infective technologies. Mr. Haegele expressed enthusiasm about joining Propedix: "I am honored to join the Propedix team and look forward to contributing to the company's growth and success. I am confident that the Company's management team's decades of experience in developing and commercializing dermatological and anti-infective technologies will establish Propedix as a leader in innovative biopharma delivery and formulation solutions." About Propedix Propedix is a leading biopharma and consumer health company dedicated to advancing innovative treatments in topical dermatology and anti-infectives. Through a commitment to innovation, Propedix strives to provide effective, clinically tested solutions to fungal conditions. The Propedix team works diligently to expand the world of antifungal and anti-pathogen treatment through the use of their propriety delivery and formulation technology. Propedix has established itself as a trusted name in the industry, centering around improving the quality of life for each patient. About Dryello™ Dryello™ is a novel treatment for Athlete's foot that has been clinically tested to demonstrate strong effectiveness in mycological (fungal) cure and the reduction of symptoms associated with such infections including itch, perspiration, maceration, and scaling. Dryello's unique technology formulation and the supporting clinical data will be made available to the public upon commercial launch by early summer. View original content to download multimedia: SOURCE Propedix Inc.
Yahoo
an hour ago
- Yahoo
Cancer still tops high-cost health claims but muscle and orthopedic conditions are making surprise surge: Sun Life report
13th-annual high-cost claims analysis highlights soaring healthcare expenses with cancer, cardiovascular and musculoskeletal leading the way WELLESLEY, Mass., June 4, 2025 /PRNewswire/ -- Sun Life, the nation's leading independent stop-loss provider for self-funded employers, today released its 13th annual high-cost claim and injectable drugs trend analysis, examining more than 65,000 health claims from 3,000 employers between 2021 and 2024. Overall, million-dollar stop-loss claims are on the rise, increasing by 29% this year when looking at claims-per-million-covered employees, and are up 61% over the past four years. "Sun Life's annual high-cost claims report illustrates the escalating nature of healthcare costs and the growing financial burden on employers and the healthcare system," said Jen Collier, president of Health and Risk Solutions, Sun Life U.S. "By analyzing our clinical data annually, we are able to create solutions with targeted interventions and personalized care navigation that can have a significant impact on both health outcomes and cost containment." Cancer Leads as Top Cost Driver Cancer once again tops the list as the most frequent and costly condition, with malignant neoplasms (solid tumors) generating $1.2 billion in spending across approximately 5,000 claims in 2024—triple the cost of the second-leading condition, cardiovascular. While blood cancers (Leukemia, Lymphoma, Multiple Myeloma) moved down one spot, they remain in the top five categories with nearly 900 members experiencing a high-cost claim annually. Additional Key Findings: Orthopedics/Musculoskeletal (Ortho/MSK) conditions are increasing in frequency, placing the category in the top three for the first time. While the average cost is lower than most categories at $116,000, it is second in claim frequency only to malignant neoplasms. The total spend in the category is $1.18 billion for the reporting period. The average cost for congenital anomaly claims increased 70% since 2021. More than 450 members experienced a congenital anomaly with an average claim cost of $335,000. The highest-cost claim in this category in 2024 was approximately $12 million. Uncategorized drugs' have emerged as one of the highest-cost categories among injectable drugs, driven in part by gene therapies. This category encompasses newly approved medications, compounded formulations, and drugs used in experimental treatments during clinical trials. Even though the average treatment cost is relatively low at $5,900, two members received gene therapies totaling $6.8 million in 2024, catapulting the category to #16 on the list. Eight of the 10 highest-cost drugs are primarily used in the treatment of cancer. Keytruda was the costliest cancer treatment and the highest overall drug with $84.4 million in spend. Durvalumab was added to this year's list due to a spike in utilization over the four-year and one-year views, with 78 members using the drug in 2024. "As a physician, I am keenly aware that factors such as chronic conditions, medical advancements, drug spend, and delayed care are putting pressure on employers and their workforces," said Dr. Miles Varn, chief medical officer, Sun Life U.S. and head of PinnacleCare. "Through Sun Life's dedicated programs and resources, our clinical team can engage members early in their healthcare journey – helping to close care gaps by finding appropriate care and services – ultimately improving the outcomes for individuals while creating more sustainable costs for employers." As a stop-loss provider, Sun Life covers high-cost claims for employers who self-fund their employee health plans. According to KFF, an independent non-profit organization focused on national health issues, 63% of covered workers in the U.S. are in a plan that is self-funded. To learn more, register for Sun Life's High-Cost Claims and Injectables webinar on June 5 featuring Jennifer Collier, Sun Life's president of Health and Risk Solutions, Dr. Miles Varn, chief medical officer, Mike Huppert, AVP, Actuarial and Risk Management, and Ryan Murphy, assistant vice president, Health Capabilities and Strategic Growth. About Sun LifeSun Life is a leading international financial services organization providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of March 31, 2025, Sun Life had total assets under management of $1.55 trillion. For more information, please visit Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF. Sun Life U.S. is one of the largest providers of employee and government benefits, helping approximately 50 million Americans access the care and coverage they need. Through employers, industry partners and government programs, Sun Life U.S. offers a portfolio of benefits and services, including dental, vision, disability, absence management, life, supplemental health, medical stop-loss insurance, and healthcare navigation. Sun Life employs more than 8,300 people in the U.S., including associates in our partner dental practices and affiliated companies in asset management. Group insurance policies are issued by Sun Life Assurance Company of Canada (Wellesley Hills, Mass.), except in New York, where policies are issued by Sun Life and Health Insurance Company (U.S.) (Lansing, Mich.). Media contact:Anjie 469-938-1050 Connect with Sun Life U.S. View original content to download multimedia: SOURCE Sun Life U.S. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
